Xlife Sciences AG Confirms Strategic Portfolio Growth and Sustainable Value in 2024 Valuation Report

Xlife Sciences AG publishes its 2024 Valuation Report, valuing its portfolio at CHF 617.4–754.7 million. Five key project companies represent 88% of the portfolio, with 76% in the Proof of Concept phase. Following FUSE-AI’s potential listing, Xlife Sciences targets the U.S. market for broader growth. CYLAD Consulting conducted the independent valuation using rNPV methodology.

Xlife Sciences AG (SIX: XLS), a Swiss-based life sciences incubator and accelerator, releases its 2024 Valuation Report, confirming sustainable value creation and strategic scaling across its portfolio of project companies. The valuation, conducted by independent firm CYLAD Consulting, assesses the company’s holdings as of 31 December 2024.

The report evaluates 16 project companies currently under the Xlife Sciences umbrella. CYLAD Consulting bases its analysis on a combination of financial forecasts, strategic plans, and qualitative assessments, including site visits and discussions with project company leadership. The methodology applied is the risk-adjusted net present value (rNPV), a recognised valuation approach in the life sciences sector. This method accounts for development risks and cost of capital associated with each project.

The 2024 valuation estimates Xlife Sciences’ portfolio value to be in the range of CHF 617.4 million to CHF 754.7 million. This reflects a modest increase from the previous year’s range of CHF 611.7 million to CHF 747.8 million.

Leading projects drive majority of value

Five of the project companies represent 88 percent of the total portfolio value:

• alytas therapeutics GmbH
• VERAXA Biotech AG
• inflamed pharma GmbH
• Inventum Genetics GmbH
• FUSE-AI GmbH

Among the four strategic focus areas of Xlife Sciences, the Technology Platforms segment contributes the largest share of value at 50 percent, followed by Biotechnology/Therapies at 38 percent. The remaining share is distributed across Medical Technology and Artificial Intelligence/Digital Health.

According to the valuation, 76 percent of the portfolio’s value is derived from projects in the Proof of Concept phase, with an additional 12 percent attributed to projects that are already operational in the market.

Focus on strategic development and market entry

Commenting on the report, Oliver R. Baumann, CEO of Xlife Sciences AG, states:

“The 2024 Valuation Report again confirms the strong potential of our portfolio. Our model of accelerating innovative projects from top academic institutions toward commercialization continues to create substantial value for our shareholders. We remain focused on strategic project development and selective international expansion, including the validation of our business model by transaction/partial exits as with the most recent VERAXA Biotech AG announcement.”

Xlife Sciences’ strategy of bridging research and development with commercial healthcare applications remains core to its operations. The firm supports high-potential research in key areas and assists in the transition toward viable market solutions.

Capital market strategy and international scaling

One of the notable developments highlighted in the report is the planned capital market transaction of FUSE-AI GmbH, which has attracted significant investor interest. An initial offer from Pineapple Power Corporation PLC to acquire the company valued it at EUR 80–90 million with an aim to list it on the London Stock Exchange (LSE). Following a detailed review of additional offers, and in consultation with strategic co-investors and stakeholders, a decision is taken to align any future listing with the current valuation range of EUR 100–115 million.

The company now targets a potential listing in the United States, where it aims to secure faster scalability, broader market access, and stronger capital backing for growth. The approach is in line with the firm’s strategic goals of expanding international presence and validating business models through successful market entries and exits.

The complete 2024 Valuation Report is available at: https://www.xlifesciences.ch/en/news-and-key-figures

About Xlife Sciences AG

Xlife Sciences AG (SIX: XLS) is a Swiss company that specialises in the value development and commercialisation of academic research in life sciences. It acts as an incubator and accelerator, supporting projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health. Xlife Sciences works to address unmet medical needs by helping research projects transition from concept to market-ready solutions.

About CYLAD Consulting

CYLAD Consulting is an international management and strategy consultancy established in 2007. With a workforce of approximately 130 professionals and 17 partners, the firm operates across France, Germany, Switzerland, Australia, and Canada. CYLAD supports both private and public sector clients with expertise in sectors such as aerospace, defence, machinery, pharmaceuticals, medtech, biotech, energy, and electronics. Recognised by Forbes and Statista among top consulting firms, CYLAD delivers services focused on strategic growth, transformation, performance improvement, and interim management.